NCT02399748 A Long-term Study for the Outcome of Pompe Disease
| NCT ID | NCT02399748 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Pompe Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2007-04 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2007-04 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospectively follow patients with Pompe disease underwent enzyme replacement therapy.
Eligibility Criteria
Inclusion Criteria: Confirm diagnosis with Pompe disease, is or is preparing receiving enzyme replacement therapy Exclusion Criteria: No
Contact & Investigator
Yin-Hsiu Chien
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT02399748 clinical trial?
This trial is open to participants of all sexes, studying Pompe Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02399748 currently recruiting?
Yes, NCT02399748 is actively recruiting participants. Contact the research team at chienyh@ntu.edu.tw for enrollment information.
Where is the NCT02399748 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT02399748 clinical trial?
NCT02399748 is sponsored by National Taiwan University Hospital. The principal investigator is Yin-Hsiu Chien at National Taiwan University Hospital. The trial plans to enroll 50 participants.